First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

Trial Profile

First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Tisotumab-vedotin (Primary)
  • Indications Bladder cancer; Cervical cancer; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Genmab
  • Most Recent Events

    • 12 Sep 2017 Results of the full data set from the dose-escalation part (n=27), presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Full efficacy data for all 30 patients with relapsed, recurrent, or metastatic cervical cancer will be available at time of presentation at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=19) of cervical cancer cohort presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top